TABLE 2.
Summary of the biological activities altered by mutations in EBOV GP1
| Mutation(s) | GP1 incorporation | Transduction efficiency | Competition efficiency | Cathepsin cleavage | Biological classificationb |
|---|---|---|---|---|---|
| ΔO | +++ | 100 | 100 | +++ | Wild type |
| K84A | ++ | 55.4 | 82.0 | +++ | IV |
| W86A | +/− | 0 | 25.2 | NAa | I |
| G87A/F88A | +++ | 0 | 45.0 | +++ | II |
| Y109A/I113T | +/− | 0.4 | NA | NA | I |
| K114A/K115A | +++ | 2.1 | 35.5 | +++ | II |
| R134A | +++ | 65 | 98.4 | +++ | IV |
| K140A | +++ | 25.1 | 44.7 | +++ | II |
| G143A | +++ | 1 | 50.0 | + | II |
| P146A/C147A | +++ | 0.2 | 41.5 | +/− | III |
| D150A | +++ | 67.9 | 81.2 | +++ | IV |
| F153A/H154A | +++ | 0 | 40.2 | +/− | III |
| F159A | ++ | 0 | 39.8 | +/− | III |
| F160A | + | 26.6 | 35.0 | +/− | I |
| Y162A | ++ | 44.3 | 61.3 | ++ | II |
| R164A/L165A | ++ | 52.2 | 84.0 | +++ | IV |
| T175A/F176A | +/− | 0.5 | NA | NA | I |
| G179A | +/− | 7.5 | NA | NA | I |
| Y214A | +/− | 0.1 | NA | NA | I |
| Y221A/Q222A | +/− | 1.7 | NA | NA | I |
| P251A/Q252A | +/− | 1.3 | NA | NA | I |
| T260A/I261A | +/− | 32.6 | NA | NA | I |
| N269A/T270A | +/− | 24.7 | NA | NA | I |
| E305A/E306A | ++ | 37.8 | 102.9 | ++ | IV |
a
NA, not applicable.
b
Mutants were classified by their defect in GP1 incorporation (I), receptor binding (II), conformational defect (III), or postbinding, postcleavage entry steps (IV).